drugset / Trial / NCT06942923

A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity

NCT06942923

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.

Timeline

Start
2025-04-22
Primary completion
2025-09-29
Completion
2025-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4144 Unknown Oral

Indications

No indication recorded.